Comparison

CD120a. TNF-R I (p55/p60)

Item no. 20-321-175103
Manufacturer GENWAY
Amount 0.1 mg
Category
Type Antibody
Clone H398
Specific against other
ECLASS 10.1 32160702
ECLASS 11.0 32160702
UNSPSC 12352203
Alias GWB-FB7EDD
Similar products 20-321-175103
Available
Genway ID:
GWB-FB7EDD
Clone:
H398
Applications:
The antibody is an antagonistic antibody useful for cell culture experiments. flow cytometry and immunohistology on frozen sections. Furthermore the antibody is useful for immuno precipitation. Western blotting and immuno assays. Be aware that the antibody competes with TNF-alpha. The antibody reacts with the extra-cellular part of the TNF-R I. It also reacts with the soluble receptor. TNF-R I is present on most cell types and is considered to play a prominent role in cell stimulation by TNF-alpha. Induction of cytotoxicity and other functions are mediated largely via TNF-R I. The antibody is cross reactive with rat TNF-RI.
Function:
Receptor for TNFSF2/TNF-alpha and homotrimeric TNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes to the induction of non-cytocidal TNF effects including anti-viral state and activation of the acid sphingomyelinase.
Subunit:
Binding of TNF to the extracellular domain leads to homotrimerization. The aggregated death domains provide a novel molecular interface that interacts specifically with the death domain of TRADD. Various TRADD-interacting proteins such as TRAFS RIPK1 and possibly FADD are recruited to the complex by their association with TRADD. This complex activates at least two distinct signaling cascades apoptosis and NF-kappa-B signaling. Interacts with BAG4 BRE GRB2 SQSTM1 and TRPC4AP. Interacts with HCV core protein.
Subcellular Location:
Cell membrane; Single-pass type I membrane protein. Secreted.
Domain:
The domain that induces A-SMASE is probably identical to the death domain. The N-SMASE activation domain (NSD) is both necessary and sufficient for activation of N-SMASE.
Domain:
Both the cytoplasmic membrane-proximal region and the C-terminal region containing the death domain are involved in the interaction with TRPC4AP (By similarity).
Ptm:
The soluble form is produced from the membrane form by proteolytic processing.
Disease:
Defects in TNFRSF1A are the cause of familial hibernian fever (FHF) [MIM:142680]; also known as tumor necrosis factor receptor-associated periodic syndrome (TRAPS). FHF is an autosomal dominant disease characterized by recurrent fever abdominal pain localized tender skin lesions and myalgia.
Similarity:
Contains 1 death domain.
Similarity:
Contains 4 TNFR-Cys repeats. Summary: The protein encoded by this gene is a member of the TNF-receptor superfamily. This protein is one of the major receptors for the tumor necrosis factor-alpha. This receptor can activate NF-kappaB mediate apoptosis and function as a regulator of inflammation. Antiapoptotic protein BCL2-associated athanogene 4 (BAG4/SODD) and adaptor proteins TRADD and TRAF2 have been shown to interact with this receptor and thus play regulatory roles in the signal transduction mediated by the receptor. Germline mutations of the extracellular domains of this receptor were found to be associated with the autosomal dominant periodic fever syndrome. The impaired receptor clearance is thought to be a mechanism of the disease. [1] Yu X. Wang L. Yan C. and Li X. et al. Expression and localization of tumor necrosis factor receptor 1 protein in the chorionic villi in early normal and spontaneous abortion[2] Mavri A. Bastelica D. Poggi M. Morange P. Peiretti F. Verdier M. Juhan-Vague I. and Alessi M. C. Polymorphism A36G of the tumor necrosis factor receptor 1 gene is associated with PAI-1 levels in obese women[3] van Horssen R. Rens J. A. Schipper D. Eggermont A. M. and ten Hagen T. L. EMAP-II facilitates TNF-R1 apoptotic signalling in endothelial cells and induces TRADD mobilization[4] Manki A. Nishikomori R. Nakata-Hizume M. Kunitomi T. Takei S. Urakami T. and Morishima T. Tumor necrosis factor receptor-associated periodic syndrome mimicking systemic juvenile idiopathic arthritis[5] Nomura A. Ujike H. Tanaka Y. Kishimoto M. Otani K. Morita Y. Morio A. Harano M. Inada T. Yamada M. Komiyama T. Hori T. et al. Association study of the tumor necrosis factor-alpha gene and its 1A receptor gene with methamphetamine dependence[6] Schall T. J. Lewis M. Koller K. J. Lee A. Rice G. C. Wong G. H. W. Getanaga T. Granger G. A. Lentz R. Raab H. et al. Molecular cloning and expression of a receptor for human tumor necrosis factor. [7] Loetscher H. Pan Y. -C. E. Lahm H. -W. Gentz R. Brockhaus M. Tabuchi H. Lesslauer W. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. [8] Nophar Y. Kemper O. Brakebusch C. Engelmann H. Zwang R. Aderka D. Holtmann H. Wallach D. Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R cloned using amino acid sequence data of its soluble form encodes both the cell surface and a soluble form of the receptor. [9] Himmler A. Maurer-Fogy I. Kroenke M. Scheurich P. Pfizenmaier K. Lantz M. Olsson I. Hauptmann R. Stratowa C. Adolf G. R. et al. Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative tumor necrosis factor-binding protein. [10] Gray P. W. Barrett K. Chantry D. Turner M. Feldman M. Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 0.1 mg
Available: In stock
available

Delivery expected until 10/30/2025 

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close